



## (51) International Patent Classification:

*C07K 16/30* (2006.01) *A61P 35/00* (2006.01)  
*C07K 16/28* (2006.01) *A61K 39/00* (2006.01)

## (21) International Application Number:

PCT/US2019/059271

## (22) International Filing Date:

31 October 2019 (31.10.2019)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

62/754,577 01 November 2018 (01.11.2018) US  
62/774,167 30 November 2018 (30.11.2018) US  
62/774,856 03 December 2018 (03.12.2018) US  
62/777,066 07 December 2018 (07.12.2018) US  
62/845,817 09 May 2019 (09.05.2019) US


(71) Applicants: **JUNO THERAPEUTICS, INC.** [US/US];  
400 Dexter Avenue N., Suite 1200, Seattle, Washington  
98109 (US). **MEMORIAL SLOAN KETTERING CAN-**

**CER CENTER** [US/US]; 1275 York Avenue, New York,  
New York 10065 (US).

(72) Inventors: **SATHER, Blythe D.**; 400 Dexter Avenue N.,  
Suite 1200, Seattle, Washington 98109 (US). **SMITH, Eric  
L.**; 1275 York Avenue, New York, New York 10065 (US).  
**TAREEN, Semih**; 400 Dexter Ave. N, Suite 1200, Seattle,  
Washington 98109 (US). **CHEN, Aye**; 400 Dexter Ave. N,  
Suite 1200, Seattle, Washington 98109 (US). **DE IMUS,  
Cyr**; 400 Dexter Ave. N, Suite 1200, Seattle, Washington  
98109 (US). **HESS, Erik**; 400 Dexter Ave. N, Suite 1200,  
Seattle, Washington 98109 (US). **OLSHEFSKY, Audrey**;  
400 Dexter Ave. N, Suite 1200, Seattle, Washington 98109  
(US). **PONKO, Stefan**; 400 Dexter Ave. N, Suite 1200,  
Seattle, Washington 98109 (US). **STIRNER, Mariana Co-**  
**ta**; 400 Dexter Ave. N, Suite 1200, Seattle, Washington  
98109 (US).

(74) Agent: **AHN, Sejin** et al.; Morrison & Foerster LLP,  
12531 High Bluff Drive, Suite 100, San Diego, California  
92130-2040 (US).

(54) Title: METHODS FOR TREATMENT USING CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR B-CELL MATURATION ANTIGEN



(57) Abstract: Provided herein are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain plasma cell malignancy. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs) specific to B-cell maturation antigen (BCMA). In some embodiments, the methods are for treating subjects with multiple myeloma (MM). Also provided are genetically engineered cells containing such BCMA-binding receptors for uses in adoptive cell therapy.

[Continued on next page]

**(81) Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

**(84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

**Published:**

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*